- Home
- NCMI vs XOMAP Comparison
NCMI vs XOMAP Comparison
Compare NCMI & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCMI
- XOMAP
- Stock Information
- Founded
- NCMI 2005
- XOMAP N/A
- Country
- NCMI United States
- XOMAP United States
- Employees
- NCMI N/A
- XOMAP 13
- Industry
- NCMI Advertising
- XOMAP Biotechnology: Pharmaceutical Preparations
- Sector
- NCMI Consumer Discretionary
- XOMAP Health Care
- Exchange
- NCMI Nasdaq
- XOMAP Nasdaq
- Market Cap
- NCMI N/A
- XOMAP N/A
- IPO Year
- NCMI 2007
- XOMAP N/A
- Fundamental
- Price
- NCMI $5.07
- XOMAP $25.30
- Analyst Decision
- NCMI Strong Buy
- XOMAP
- Analyst Count
- NCMI 5
- XOMAP 0
- Target Price
- NCMI $7.60
- XOMAP N/A
- AVG Volume (30 Days)
- NCMI 867.7K
- XOMAP N/A
- Earning Date
- NCMI 05-06-2025
- XOMAP N/A
- Dividend Yield
- NCMI 1.18%
- XOMAP N/A
- EPS Growth
- NCMI N/A
- XOMAP N/A
- EPS
- NCMI N/A
- XOMAP N/A
- Revenue
- NCMI $238,300,000.00
- XOMAP N/A
- Revenue This Year
- NCMI $15.11
- XOMAP N/A
- Revenue Next Year
- NCMI $9.16
- XOMAP N/A
- P/E Ratio
- NCMI N/A
- XOMAP N/A
- Revenue Growth
- NCMI 42.10
- XOMAP N/A
- 52 Week Low
- NCMI $4.12
- XOMAP N/A
- 52 Week High
- NCMI $7.60
- XOMAP N/A
- Technical
- Relative Strength Index (RSI)
- NCMI 34.36
- XOMAP 41.77
- Support Level
- NCMI $4.12
- XOMAP $25.21
- Resistance Level
- NCMI $5.88
- XOMAP $26.28
- Average True Range (ATR)
- NCMI 0.32
- XOMAP 0.19
- MACD
- NCMI -0.08
- XOMAP -0.05
- Stochastic Oscillator
- NCMI 46.12
- XOMAP 8.41
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.